What did @cbcnews actually say?
This video isn't a medical explainer. It's a documentary clip about musician Breton Lalama's experience starting testosterone, with a focus on what happened to their singing voice. Lalama describes voice changes beginning around two months in, a period of depression tied to losing vocal range, and an eventual reframing of the loss. The clinical-adjacent claim worth examining: "when somebody first starts taking testosterone there's changes in the textures of the muscle tissues" that alter how vocalization feels, range, and tone. That's the scientific assertion on the table. The rest is personal narrative, and it's handled honestly.
Lalama also says losing the old voice was "a natural thing that I was good at" and that "it is not that now." That kind of candor about post-transition grief is rare in media coverage and genuinely useful for people considering hormone therapy.
Does the science back this up?
Mostly, yes. The mechanism Lalama describes, tissue-level changes affecting vocal function, is real, though the framing is slightly imprecise. Testosterone causes laryngeal growth and changes to the vocal folds themselves, not just surrounding muscle tissue. The distinction matters.
Research consistently shows that testosterone administration in transgender men and nonbinary people assigned female at birth causes measurable changes to fundamental frequency, vocal fold length, and laryngeal cartilage. Adler et al. (2012, Journal of Voice) documented that vocal changes typically begin within weeks of starting testosterone and continue for months to years. A 2021 study by Nygren et al. in the Journal of Voice found that while speaking voice typically masculinizes predictably, singing voice is far more variable, with some individuals experiencing significant range loss that does not fully recover. That matches exactly what Lalama describes.
The "muscle tissue" framing is an oversimplification. The primary driver is growth of the vocal folds and larynx under androgen influence, similar to what happens during male puberty, not a generalized muscle texture change. But the experiential description, feeling different to vocalize, range shifting, tone changing, is clinically consistent.
What did they get wrong (or right)?
The "changes in the textures of the muscle tissues" line is the one place the science gets a little loose. Vocal fold tissue does change under testosterone, but calling it a muscle texture shift undersells the structural reality: the vocal folds lengthen, the larynx descends, and cartilage remodels. Saying it "feels different to vocalize" is accurate. The mechanism explanation is imprecise but not harmful.
What they got right is more significant. The grief narrative is clinically validated. A 2019 paper by Hancock and Siegfriedt in the American Journal of Speech-Language Pathology specifically documented psychological distress tied to singing voice loss in transgender men during early hormone therapy. Lalama's framing, "I lose in order to live," reflects the kind of cost-benefit processing that actual patients report. That's not dramatization. That's what the data looks like when it has a face.
The description of early "euphoria" at hearing one's voice shift toward gender congruence is also consistent with research on gender dysphoria relief during early transition (van der Miesen et al., 2018, Adolescent Health, Medicine and Therapeutics).
What should you actually know?
If you're considering testosterone therapy and you sing, or your voice matters professionally, this video is doing you a service by not sugarcoating the trade-offs. Here's what the clinical picture actually looks like.
- Voice changes on testosterone are not fully predictable. Speaking voice masculinizes in most people. Singing range changes are highly variable and not guaranteed to settle into a stable new normal quickly.
- The timeline is not short. Changes can continue for two or more years after starting testosterone, according to Adler et al. (2012).
- Voice training with a speech-language pathologist who specializes in transgender voice can help optimize outcomes during the transition period. This is underutilized.
- The grief response Lalama describes is not unusual or a sign that something went wrong. It's a documented psychological feature of voice transition, separate from regret about hormone therapy overall.
- Testosterone therapy for gender-affirming purposes is distinct from TRT for hypogonadism in cisgender men. Doses, goals, and monitoring protocols differ. Do not assume protocols are interchangeable.
The video's value is not in its clinical precision. It's in showing what the experience actually looks like, which is something a lot of hormone therapy content skips entirely.